Iterum shareholders reject say-on-pay, share increase, and equity plan at AGM

Iterum Therapeutics plc

David Kelly elected Class I director with 10.8M for, 2.8M against, 0.7M abstain, 8.2M broker non-votes.
Say-on-pay failed: 5.4M for (38.5%), 8.4M against, 0.5M abstain.
Share capital increase to $2.6M (add 80M shares) rejected: 6.5M for, 15.8M against.
Equity incentive plan amendment to add 4M shares rejected: 2.5M for, 11.3M against.
Allotment authority and pre-emption opt-out also failed by wide margins.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.